{"id":6953,"date":"2017-06-01T09:19:45","date_gmt":"2017-06-01T13:19:45","guid":{"rendered":"https:\/\/medicarereport.org\/?p=6953"},"modified":"2017-06-01T09:19:45","modified_gmt":"2017-06-01T13:19:45","slug":"mylan-may-have-overcharged-taxpayers-by-1-27-billion-for-epipens-hhs-says","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=6953","title":{"rendered":"Mylan may have overcharged taxpayers by $1.27 billion for EpiPens, HHS says"},"content":{"rendered":"<p>(By Ike Swetlitz for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap\">M<\/span>ylan may have overcharged taxpayers as much as $1.27 billion over 10 years for its\u00a0signature EpiPens, according to an <a href=\"https:\/\/www.grassley.senate.gov\/sites\/default\/files\/constituents\/HHS%20OIG%202nd%20EpiPen%20calculation%20letter%20for%20Senate%20Judiciary%20May%2031%202017_Redacted.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">analysis<\/a><sup class=\"footnote\">1<\/sup> released Wednesday\u00a0by the Department of Health and Human Services\u2019s watchdog. <a href=\"https:\/\/www.statnews.com\/2017\/05\/31\/mylan-medicaid\/\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Ike Swetlitz for STAT) Mylan may have overcharged taxpayers as much as $1.27 billion over 10 years for its\u00a0signature<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-6953","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6953"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6953\/revisions"}],"predecessor-version":[{"id":6954,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6953\/revisions\/6954"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}